- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01860170
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
A Phase I Trial of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
Study Overview
Status
Conditions
Detailed Description
It is hypothesized that the administration of an early and short course cyclophosphamide and bortezomib after allogeneic hematopoietic stem cell transplantationin in the setting of matched related or unrelated donor transplantation using a standard reduced-intensity conditioning regimen is feasible.
The study is a phase I study. The primary objective of the study is to determine the feasibility and safety of increasing doses of bortezomib administered post-transplant in conjunction with fixed high dose cyclophosphamide, also administered post-transplant in the setting of reduced-intensity allogeneic hematopoietic stem cell transplant, as GVHD prophylaxis strategy. Eligible patients will receive a conditioning regimen based on a combination of fludarabine and busulfan with or without rATG.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- 8 out of 8 matched related or unrelated donor
- Age > 18 years
- Good performance status with a Karnofsky score >/= to 70%
- No evidence of progressive bacterial, viral or fungal infection despite adequate treatment
- Creatinine clearance > 40 mL/min/1.72m2
- Total bilirubin < 1.5 and ALT and AST < 2 times the upper limit of normal
- Cardiac ejection fraction > 40%
- DLCO > 50%
- Negative pregnancy test
- Negative HIV serology
- Able to provide informed consent
- Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of bortezomib, or agree to completely abstain from heterosexual intercourse.
- Male subjects, even if surgically sterilized (ie, status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.
Exclusion Criteria:
- Age <18 years
- Poor performance status (<70%)
- Active infections
- Abnormal creatinine clearance <40ml/min
- Elevated bilirubin >1.5 and ALT and AST .2 times the upper limit of normal
- Poor ejection fraction <40%
- DLCO <50%
- Pregnant female.
- HIV positive
- Inability to provide informed consent
- Patient has >/= Grade 2 peripheral neuropathy
- Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
- Patient has hypersensitivity to bortezomib, boron, or mannitol.
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
- Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort 1-Bortezomib (Velcade®)
Bortezomib (Velcade®) 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
|
Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1. Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0. Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Other Names:
|
Active Comparator: Cohort 2-Bortezomib (Velcade®)
Bortezomib (Velcade®) 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
|
Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1. Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0. Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Other Names:
|
Active Comparator: Cohort 3-Bortezomib (Velcade®)
Bortezomib (Velcade®) 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
|
Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1. Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0. Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicity
Time Frame: Assessed daily (while inpatient) through clinical and laboratory examination up to 90 days.
|
Grade 3 non-hematologic Common Toxicity Criteria toxicity directly related to bortezomib (such as peripheral neuropathy) or Grade 2 or > hepatic bilirubin Common Toxicity Criteria Graft failure
|
Assessed daily (while inpatient) through clinical and laboratory examination up to 90 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engraftment
Time Frame: Assessed daily by laboratory evaluation until engraftment or up to 90 days.
|
Neutrophil engraftment is defined as achieving an absolute neutrophil count (ANC) > 0.5 109/L for 3 consecutive measurements on different days. The first of the 3 days will be considered the day of neutrophil engraftment. Platelet engraftment is defined as platelet count > 20 109/L for 3 consecutive measurements over at least 3 days. The first of the 3 days will be considered the day of platelet engraftment. In this study, graft failure is defined as lack of achieving neutrophil engraftment by day 22 and donor chimerism > 50% by day 45. |
Assessed daily by laboratory evaluation until engraftment or up to 90 days.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GVHD
Time Frame: Assessed routinely by clinical and pathological evaluation. Acute GVHD will be assessed up to day 150 post-transplant. Chronic GVHD will be assess up to 2 years post-transplant.
|
aGVHD onset at a certain grade will be used to calculate the cumulative incidence for that grade (e.g., onset of grade 70 post-transplant , time to grade III is 70 days). This end point will be evaluated through day 150 post-transplant. The diagnosis of aGVHD is based on clinical and pathological evaluation by the treating physician. The first day of cGVHD will be used to calculate the cumulative incidence of cGVHD. The diagnosis of cGVHD is based on clinical and pathological evaluation by the treating physician. |
Assessed routinely by clinical and pathological evaluation. Acute GVHD will be assessed up to day 150 post-transplant. Chronic GVHD will be assess up to 2 years post-transplant.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: A. Samer Al-Homsi, MD, Spectrum Health Hospitals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms
- Neoplasms by Site
- Hematologic Diseases
- Hematologic Neoplasms
- Graft vs Host Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Bortezomib
Other Study ID Numbers
- 2013-083 (Barbara Ann Karmanos Cancer Institute)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancy
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Henry Ford Health SystemRecruitingHematological MalignancyUnited States
-
SanofiCompletedHematological MalignancyGreece, Spain, Peru, Israel, United States, Argentina, Belgium, Brazil, Chile, Finland, France, Italy, Mexico, Russian Federation, Turkey, Ukraine, United Kingdom
-
University of CopenhagenZealand University HospitalEnrolling by invitationHematological MalignancyDenmark
-
Washington University School of MedicineBarnes-Jewish HospitalTerminatedHematological MalignancyUnited States
-
Institut Paoli-CalmettesCompletedHematological MalignancyFrance
-
Peking University People's HospitalSanofiRecruitingHematological MalignancyChina
-
M.D. Anderson Cancer CenterRecruiting
-
Beckman Coulter, Inc.Completed
-
Fate TherapeuticsTerminatedHematological MalignancyUnited States
Clinical Trials on Cohort 1-Bortezomib (Velcade ®)
-
The Rogosin InstituteWeill Medical College of Cornell UniversityCompleted
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Swiss Group for Clinical Cancer ResearchEuropean Mantle Cell Lymphoma NetworkTerminatedMantle Cell LymphomaItaly, Germany, Switzerland
-
GlaxoSmithKlineWithdrawn
-
Yonsei UniversityUnknownMultiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell TransplantationKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedHeart Transplantation | Heart Transplant | Primary Heart TransplantUnited States
-
University Hospital, Basel, SwitzerlandTerminatedDysferlinopathySwitzerland
-
University of ArkansasMillennium Pharmaceuticals, Inc.TerminatedMultiple MyelomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisTerminatedSTAGE IIIB OR IV NON-SMALL CELL LUNG CANCERFrance
-
Prof. Dr. Clemens SchmittCharite University, Berlin, Germany; Janssen-Cilag Ltd.Active, not recruitingDiffuse Large B Cell LymphomaGermany